Drugs / MMR vaccine
MMR vaccine
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02589678 | Aug 2015 → May 2017 | — | Emory University | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04475081 | Sep 2020 → May 2022 | infectious disease with sepsis | Louisiana State University Health Sciences Center in New Orleans | Completed | No outcome recorded |
| Phase 3 | NCT03547271 | Dec 2018 → May 2023 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | Mixed |
| Phase 48 trials · 2 met primary | ||||||
| Phase 4 | NCT06920069 | May 2025 → Jul 2030 expected | poliomyelitis | Institute of Medical Biology, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05432141 | Jun → Sep 2022 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT04111432 | Jul → Nov 2019 | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT03368495 | Nov 2015 → Jun 2018 | — | Alba Maria Ropero | Completed | Met primary |
| Phase 4 | NCT02253407 | Sep 2014 → Feb 2016 | primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Serum Institute of India Pvt. Ltd. | Completed | Met primary |
| Phase 4 | NCT01770119 | Apr 2013 → Apr 2022 | measles | Klara M. Pósfay Barbe | Unknown | No outcome recorded |
| Phase 4 | NCT01777529 | Oct 2012 → Jan 2013 | measles, mumps infectious disease, rubella | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Completed | No outcome recorded |
| Phase 4 | NCT02724852 | Jul 2011 → Sep 2013 | HIV infectious disease | Chiang Mai University | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 2 | NCT03101111 Comparator | Aug 2017 → Apr 2019 | chikungunya | Themis Bioscience GmbH | Completed | No outcome recorded |
| Phase 3 | NCT07103148 Background | Jul 2025 → Aug 2026 overdue | yellow fever | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT06806137 Background | May 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06740630 Background | Jan 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT03853785 Comparator | Feb 2020 → Feb 2021 | anogenital human papillomavirus infection | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT01553279 Background | Mar 2012 → Sep 2013 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 4 | NCT06257212 Comparator | Feb 2024 → Aug 2025 | chronic obstructive pulmonary disease | Josefin Eklöf | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-06 | GlaxoSmithKline | Regulatory GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older gsk.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-06 | GlaxoSmithKline | GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older gsk.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMR Vaccine | “An additional group with participants of 11-15 months of age will also receive at the same vaccination visit vYF and a single dose of MMR vaccine.” NCT07103148 ↗17“Eligible children in Group 2 will receive a standard dose (0.5 ml) of MMR vaccine during the first medical visit (V1).” NCT01770119 ↗ “the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.” NCT04111432 ↗ “MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.” NCT03368495 ↗ |
| Known as | M-M-R II | “receive the live attenuated M-M-R® II vaccine or placebo (sterile saline) via subcutaneous injection in the arm at a baseline visit following informed consent.” NCT04475081 ↗ |
| Known as | Measles, Mumps, and Rubella Combined Live Attenuated Vaccine | “measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml)” NCT04111432 ↗ |
| Known as | Measles, Mumps, Rubella (MMR) vaccine | “randomized control clinical trial with the live attenuated Measles, Mumps, Rubella (MMR) vaccine in healthcare workers in the greater New Orleans area” PMID 37153751 ↗ Feb 2023 |
| Known as | MMR (TV) | “MMR (TV) combined measles, mumps and rubella vaccine produced in Bio-Manguinhos” NCT01777529 ↗ |
| Known as | Mumps, measles and rubella (MMR) vaccine | “Mumps, measles and rubella (MMR) vaccine is a freeze-dried preparation of live attenuated strains of measles, mumps and rubella viruses” NCT03853785 ↗ |
| Modality | Vaccine | “Measles, mumps, and rubella vaccine (live)” NCT01553279 ↗ |
| Route | Intramuscular | “given via 0.5 mL intramuscular injection” NCT01553279 ↗ |